Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion,...

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses ...

Cormorant Asset Management sold its entire $63.63 million stake in Arcellx (775,000 shares) in Q4, completely exiting a position that represented 4.4% of its AUM. The exit proved poorly timed, as Arcellx shares surged following Gilead Sciences' takeover announcement valuing the company at $7.8 billion with an offer of $115 per share plus potentia...

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Gilead Sciences agreed to acquire Arcellx for $7.8 billion, or $115 per share in cash, plus a $5-per-share contingent value right. The acquisition strengthens Gilead's oncology portfolio by adding anito-cel, a CAR T-cell therapy for multiple myeloma with promising clinical results. Arcellx shares rose on the news and are trading near their 52-wee...